As of December 31, 2025, HLB SCIENCE Inc. was acquired by HLB Co., Ltd.. HLB SCIENCE Inc. develops biological drugs with MoA to infectious diseases. Its pipeline includes DD-S052P, a candidate that exterminates germs and eliminates endotoxins; DD-A279, a new treatment to cure Alzheimer's Diseases by controlling LPS and Gram-negative bacteria; and DD-A514, a diagnosis kit for Alzheimer's diseases. The company was formerly known as Dandi Bio Science Co.,Ltd. and changed its name to HLB SCIENCE Inc. in March 2023. The company was founded in 2016 and is based in Seoul, South Korea.
Metrics to compare | 343090 | Peers Peers - average of corresponding metrics from companies closely matching 343090: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship343090PeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.4x | |
Upside (Analyst Target) | 0.0% | 0.0% | 42.5% | |
Fair Value Upside | Unlock | 0.0% | 5.8% | Unlock |